CBC COMPREHENSIVE BIOMARKER CENTER
LIVE

Serial Number

79118333

Owner

Comprehensive Biomarker Center GmbH

Filing Date

Apr 16, 2012

Add to watchlist:

No watchlists yet
View on USPTO

CBC COMPREHENSIVE BIOMARKER CENTER Trademark

Serial Number: 79118333 • Registration: 4486693

CBC COMPREHENSIVE BIOMARKER CENTER is a trademark filed by Comprehensive Biomarker Center GmbH on April 16, 2012. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Comprehensive Biomarker Center GmbH (2 trademarks)

In Neuenheimer Feld 583

Entity Type: 98

febit holding gmbh (5 trademarks)

Im Neuenheimer Feld 519
Heidelberg , DE

Entity Type: 99

Trademark Details

Filing Date

April 16, 2012

Registration Date

February 25, 2014

Published for Opposition

December 10, 2013

Cancellation Date

April 16, 2022

Goods & Services

professional business consultation and business organization consultation in the market authorization of medicines and medical devices; planning and conducting of trade fairs for economic or advertising purposes; import-export agencies in the field of medicines and medical devices; wholesale store services and retail store services featuring medicines; business marketing services related to medicines and medical devices; commercial information and advice for consumers; wholesale store services in the chemical products sector featuring chemical and biochemical reagents for genetic analysis and testing; market reports and studies

Medical services; veterinary services; hygienic and beauty care for human beings or animals; medical and veterinary diagnostic services in preclinical and clinical settings; medical and clinical examinations

scientific and technological services, namely, scientific research, analysis and testing in the field of medicine, genetics and medical biomarkers; testing, analysis, and evaluation of medical diagnostic and biomarker preparations to assure compliance with industry standards; industrial chemical, biochemical, biological and bacteriological research and analysis; medical and scientific research information in the field of medicine, genetics and medical biomarkers; research and development of vaccines and medicines; design and testing for new product development, namely, pharmaceutical and diagnostic preparations and substances; development of pharmaceutical preparations and medicines; research and development of vaccines and medicines; testing, analyzing and evaluating new medicines; chemical research laboratories, pharmaceutical research laboratories, medical research laboratories, bacteriology research laboratories, molecular biological/biological research laboratories; medical and scientific research, namely, conducting clinical trials for others; scientific analyses in the field of chemistry, biology, molecular biology, pharmaceutics, and food technology; computer development of software in the field of the operation of therapeutic and diagnostic equipment and for the data processing for the purpose of imaging; scientific and technological services, namely, scientific research particular in the field of chemistry, genetics, biology, bioengineering, and biochemistry; chemical, biochemical, biological and bacteriological research and analysis; DNA and RNA analysis services, namely, development and research of DNA, RNA and scientific research in the field of biochemistry and biotechnology; scientific research; preparation of scientific opinions in the field of scientific research and development; advisory services relating to biotechnology, pharmaceutical research and development and genetic science; medical and scientific research, namely, the extraction or cultivation, scientific processing, and scientific analysis of biomaterials and compiling data for research purposes in the field of medical science and medical consultancy; contract research in the field of pharmacological and clinical development of medicines; scientific data analysis for scientific and technical purposes, namely, analysis of data originating from clinical trials; scientific laboratory services, namely, scientific development, research, identification, validation, analysis and interpretation of biomarkers, particularly nucleic acid based biomarkers

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Nov 13, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 13, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Feb 5, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jan 11, 2022 INTS
INVALIDATION PROCESSED
Jan 11, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 26, 2021 INTR
CANCELLED SECTION 71
Feb 26, 2021 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jun 9, 2016 NREP
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 28, 2014 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Oct 23, 2014 CRCV
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 27, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 11, 2014 FICS
FINAL DISPOSITION PROCESSED
Jun 10, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 25, 2014 FICR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
May 6, 2014 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Apr 24, 2014 CRCV
REGISTERED-PRINCIPAL REGISTER
Feb 25, 2014 R.PR
NOTIFICATION PROCESSED BY IB
Feb 2, 2014 GPNX
CHANGE OF OWNER RECEIVED FROM IB
Dec 23, 2013 CHLD
PUBLISHED FOR OPPOSITION
Dec 10, 2013 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 20, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 20, 2013 OP2R
NOTICE OF PUBLICATION
Nov 20, 2013 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 4, 2013 PREV
ASSIGNED TO LIE
Oct 25, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 10, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 20, 2013 TROA
NON-FINAL ACTION MAILED
Mar 26, 2013 CNRT
NON-FINAL ACTION WRITTEN
Mar 26, 2013 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2013 TROA
REFUSAL PROCESSED BY IB
Nov 15, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 22, 2012 RFCS
REFUSAL PROCESSED BY MPU
Oct 22, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 20, 2012 RFCR
NON-FINAL ACTION WRITTEN
Oct 19, 2012 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 19, 2012 MAFR
ASSIGNED TO EXAMINER
Oct 15, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 15, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 11, 2012 REPR